Feature | April 08, 2014| Dave Fornell

CRT-D Therapy Improves Long-term Survival in Heart Failure Patients Over ICD

Study finds clear benefits of CRT-D in MADIT-CRT long-term follow up

ICD, MADIT-CRT trial, long-term followup, ACC.14
Patients in mild heart failure who receive a cardiac resynchronization therapy defibrillator (CRT-D) device may live longer than those implanted with a traditional implantable cardioverter defibrillator (ICD), according to research presented at the American College of Cardiology’s 63rd Annual Scientific Session.
 
In the longest follow-up of CRT for patients with mild heart failure to date, the continued analysis of the landmark MADIT-CRT study showed heart failure patients with left bundle branch block (LBBB) implanted with a CRT-D had a 41 percent reduced risk of death compared to patients who had a conventional ICD. The probability of all-cause mortality at seven years was 18 percent among the CRT-D patients, compared to 29 percent in the ICD group in this subset of patients. The five-year survival rate for patients with CRT-D was close to 90 percent, and more than 80 percent of patients who received CRT therapy were still alive at seven years. 
 
In addition to the mortality benefit, the results demonstrate that these patients experienced a 62 percent relative reduction in the risk of experiencing a first heart failure event when compared to patients who did not receive CRT therapy.
 
“Based on our findings, we now have an intervention that can potentially change the outcomes for certain heart failure patients,” said Ilan Goldenberg, M.D., director of the department of cardiology, Israel’s Leviev Heart Center, Sheba Medical Center, Tel Hashomer, Israel, and one of the lead investigators of the study. “We can intervene early in the course of the disease to reduce the risk of long-term mortality in these patients.”
 
The MADIT-CRT trial was originally conducted to expand the FDA indications for CRT-D use in mild heart failure patients to prevent them from progressing from New York Heart Assn. Class I or II heart failure to advanced stage Class III or IV. 
 
Trial Details 
The Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy (MADIT-CRT) trial enrolled 1,820 patients with mild or no heart failure symptoms — including 1,281 with LBBB in this analysis — and randomized them to receive CRT-D therapy or ICD. ICDs are implanted in the right ventricle of patients at high risk of sudden cardiac death due to heart arrhythmias. When patients have a life-threatening arrhythmia, the ICD delivers an electrical shock to help restore a regular heartbeat. A CRT-D differs from an ICD in that it has a second electrode over the left ventricle of the heart to help synchronize a patient’s heartbeat and improve cardiac function.
 
Patients enrolled in the study were diagnosed with New York Heart Assn. Class I or II (mild) heart failure, left ventricular dysfunction and an ejection fraction of 30 percent or lower. The original trial followed patients for an average of 2.4 years, and the current study extended this follow-up for up to seven years from enrollment.
 
According to Goldenberg, previous studies have shown survival benefits from CRT-D in patients with moderate-to-severe symptoms, where intervention took place relatively late in the course of the disease when mortality rates are high. This study is the first to show the significant survival benefit when CRT-D is used with mildly symptomatic patients or asymptomatic patients with cardiac dysfunction.
 
The significant long-term survival benefit of CRT-D in the trial was observed only among patients with LBBB, Goldenberg said. The study does not support early intervention with CRT-D in patients without LBBB. 
 
While researchers expected to find mortality reduction in patients with left bundle branch block during long-term follow-up. “We were surprised by the consistency of results in each subgroup of these patients, regardless of age, gender or the cause or duration of heart failure,” Goldenberg said.
 
Goldenberg recommends additional research to see if similar benefits are found in patients with higher ejection fractions and among those without any symptoms of heart failure. The study was supported by an unrestricted grant from Boston Scientific, St. Paul, Minn.
 
CRT Battery Life Extended
One issue with implantable electrophysiology devices has been battery life, which has become more of an issue as survival continues to improve due to these devices. Boston Scientific, the sponsor of the MADIT-CRT trial, said the new battery technology in its CRT-Ds has lasted in this trial out to at least seven years. The vendor said longer battery life may reduce the need for additional device implants in patients with heart failure, and could help reduce healthcare costs.
 
This study was simultaneously published online in the New England Journal of Medicine at the time of presentation.
 
 

Related Content

common adult CT examinations, computed tomography, diagnostic reference levels, DRLs, radiation dose, achievable dose, AD
News | Radiation Dose Management| February 23, 2017
Using data from the world’s largest computed tomography (CT) dose index registry, researchers have established national...
ACC, Haymarket Medical Education, HME, myCME, RightSTEPS initiative, prescribing behavior, chronic heart failure
News | Heart Failure| February 22, 2017
The American College of Cardiology (ACC), Haymarket Medical Education (HME) and myCME have joined forces to develop...
Mercy, HIMSS 2017, Enterprise Davies Award, health information technology
News | Information Technology| February 21, 2017
Mercy, the fifth largest Catholic healthcare system in the nation, was named a 2016 Healthcare Information and...
News | Cardiac Diagnostics| February 17, 2017
Levels of a protein in the blood associated with heart disease are also linked to early-stage brain damage, according...
Medtronic, expanded indication, Freezor Xtra Cryoablation Catheter, AVNRT, atrioventricular nodal re-entrant tachycardia
Technology | Ablation Systems| February 16, 2017
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has approved its Freezor Xtra Cryoablation Catheter...
Mercator MedSystems, DANCE trial data, ISET, LINC, Bullfrog Micro-Infusion Device
News | Peripheral Arterial Disease (PAD)| February 15, 2017
Mercator MedSystems announced that the national co-principal investigators of the company’s DANCE trial each presented...
Biotronik, ProMRI Configurator tool, MR-conditional cardiac devices, ProMRI SystemCheck
Technology | Implantable Cardiac Monitor (ICM)| February 14, 2017
Biotronik has developed an online tool that streamlines the workflow for physicians selecting the right magnetic...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
 Intra-atrial shunt device (IASD) to lower left atrial pressure by creating a small left atrial to right atrial shunt.  Abraham said these devices are in early stage development with small studies to show proof of concept and demonstrate safety.

The Corvia Intra-atrial shunt device (IASD) lowers left atrial pressure by creating a small left atrial to right atrial shunt. Preliminary clinical studies have shown promise for these types of devices to improve HFpEF patient outcomes.

Feature | Heart Failure| February 10, 2017 | Dave Fornell
In the past few years there have been a number of device therapies developed to treat heart failure (HF).
Xarelto, rivaroxaban, COMPASS study, ends early,
News | Antiplatelet and Anticoagulation Therapies| February 09, 2017
February 9, 2017 — Janssen Research & Development LLC (Janssen) announced that the Phase 3 COMPASS trial is stopp
Overlay Init